Ceramide metabolism-related prognostic signature and immunosuppressive function of ST3GAL1 in osteosarcoma
Copyright © 2023. Published by Elsevier Inc..
Osteosarcoma is the most common primary malignant bone tumor with elevated disability and mortality rates in children and adolescents and the therapeutic effect for osteosarcoma has remained stagnant in the past 30 years. Emerging evidence has shown ceramide metabolism plays a vital role in tumor progression, but its mechanisms in osteosarcoma progression remain unknown. Through consensus clustering and LASSO regression analysis based on the osteosarcoma cohorts from TARGET database, we constructed a ceramide metabolism-related prognostic signature including ten genes for osteosarcoma, with ST3GAL1 exhibiting the highest hazard ratio. Biological signatures analysis demonstrated that ceramide metabolism was associated with immune-related pathways, immune cell infiltration and the expression of immune checkpoint genes. Single-cell profiling revealed that ceramide metabolism was enriched in myeloid, osteoblast and mesenchymal cells. The interaction between TAMs and CD8+ T cells played an essential role in osteosarcoma. ST3GAL1 regulated the SPP1-CD44 interaction between TAMs and CD8+ T cells and IL-10 secretion in TAMs through α2,3 sialic acid receptors, which inhibited CD8+ T cell function. IHC analysis showed that ST3GAL1 expression correlated with the prognosis of osteosarcoma patients. Co-culture assay revealed that upregulation of ST3GAL1 in tumor cells regulated the differentiation of TAMs and cytokine secretion. Collectively, our findings demonstrated that ceramide metabolism was associated with clinical outcome in osteosarcoma. ST3GAL1 facilitated tumor progression through regulating tumor immune microenvironment, providing a feasible therapeutic approach for patients with osteosarcoma.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
Translational oncology - 40(2024) vom: 29. Jan., Seite 101840 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zou, Yutong [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Ceramide metabolism |
|---|
| Anmerkungen: |
Date Revised 15.01.2024 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.tranon.2023.101840 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365206520 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365206520 | ||
| 003 | DE-627 | ||
| 005 | 20240116231932.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.tranon.2023.101840 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1261.xml |
| 035 | |a (DE-627)NLM365206520 | ||
| 035 | |a (NLM)38029509 | ||
| 035 | |a (PII)S1936-5233(23)00226-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zou, Yutong |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Ceramide metabolism-related prognostic signature and immunosuppressive function of ST3GAL1 in osteosarcoma |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 15.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2023. Published by Elsevier Inc. | ||
| 520 | |a Osteosarcoma is the most common primary malignant bone tumor with elevated disability and mortality rates in children and adolescents and the therapeutic effect for osteosarcoma has remained stagnant in the past 30 years. Emerging evidence has shown ceramide metabolism plays a vital role in tumor progression, but its mechanisms in osteosarcoma progression remain unknown. Through consensus clustering and LASSO regression analysis based on the osteosarcoma cohorts from TARGET database, we constructed a ceramide metabolism-related prognostic signature including ten genes for osteosarcoma, with ST3GAL1 exhibiting the highest hazard ratio. Biological signatures analysis demonstrated that ceramide metabolism was associated with immune-related pathways, immune cell infiltration and the expression of immune checkpoint genes. Single-cell profiling revealed that ceramide metabolism was enriched in myeloid, osteoblast and mesenchymal cells. The interaction between TAMs and CD8+ T cells played an essential role in osteosarcoma. ST3GAL1 regulated the SPP1-CD44 interaction between TAMs and CD8+ T cells and IL-10 secretion in TAMs through α2,3 sialic acid receptors, which inhibited CD8+ T cell function. IHC analysis showed that ST3GAL1 expression correlated with the prognosis of osteosarcoma patients. Co-culture assay revealed that upregulation of ST3GAL1 in tumor cells regulated the differentiation of TAMs and cytokine secretion. Collectively, our findings demonstrated that ceramide metabolism was associated with clinical outcome in osteosarcoma. ST3GAL1 facilitated tumor progression through regulating tumor immune microenvironment, providing a feasible therapeutic approach for patients with osteosarcoma | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Ceramide metabolism | |
| 650 | 4 | |a Osteosarcoma | |
| 650 | 4 | |a ST3GAL1 | |
| 650 | 4 | |a Siglec receptor | |
| 650 | 4 | |a TAMs | |
| 700 | 1 | |a Guo, Siyao |e verfasserin |4 aut | |
| 700 | 1 | |a Liao, Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Weidong |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Ziyun |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Junkai |e verfasserin |4 aut | |
| 700 | 1 | |a Wen, Lili |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, Xianbiao |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Translational oncology |d 2008 |g 40(2024) vom: 29. Jan., Seite 101840 |w (DE-627)NLM180720333 |x 1936-5233 |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2024 |g day:29 |g month:01 |g pages:101840 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.tranon.2023.101840 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 40 |j 2024 |b 29 |c 01 |h 101840 | ||